Previous close | 367.50 |
Open | 368.60 |
Bid | 370.00 x 0 |
Ask | 385.00 x 0 |
Day's range | 358.00 - 380.00 |
52-week range | 328.50 - 1,235.00 |
Volume | |
Avg. volume | 90,861 |
Market cap | 372.853M |
Beta (5Y monthly) | 1.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | -14.80 |
Earnings date | 18 Apr 2022 - 22 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.18 |
MaxCyte, Inc. ( LON:MXCT ) shareholders might be concerned after seeing the share price drop 28% in the last quarter...
My name is Sean Menarguez, and I'm the director of investor relations here at MaxCyte. On the call from MaxCyte, we have Doug Doerfler, president and chief executive officer; and Ron Holtz, interim chief financial officer.
Thank you for standing by, and welcome to MaxCyte's fourth quarter and full year 2021 earnings conference call. On the call from MaxCyte, we have Doug Doerfler, chief executive officer; and Amanda Murphy, chief financial officer. Earlier today, MaxCyte released financial results for the fourth quarter and full year ended December 31, 2021.